Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Inulicin (1-O-Acetylbritannilactone) 是从欧亚旋覆花中提取的一种天然产物,可抑制 VEGF 介导的Src 和FAK 活化,抑制NF-κB 活化和易位,以及抑制 LPS 诱导的PGE2产生和COX-2表达。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 432 | 现货 | ||
5 mg | ¥ 987 | 现货 | ||
10 mg | ¥ 1,520 | 现货 | ||
25 mg | ¥ 2,560 | 现货 | ||
50 mg | ¥ 3,790 | 现货 | ||
100 mg | ¥ 5,470 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,080 | 现货 |
产品描述 | Inulicin (1-O-Acetylbritannilactone), an active compound isolated from Inula Britannica L, inhibits VEGF-mediated activation of Src and FAK. |
体外活性 | Inulicin(1-O-Acetylbritannilactone)通过调节VEGF-Src-FAK信号通路,抑制血管生成和肺癌细胞增长。Inulicin剂量依赖性地抑制了血管内皮生长因子(VEGF)诱导的人脐带血管内皮细胞(HUVECs)的增殖、迁移和毛细血管结构形成。在A549细胞中,观察到Src和FAK磷酸化水平显著增加,而Inulicin处理(5 μM和10 μM)可抑制这两者的磷酸化。Src和FAK对癌细胞增殖都是重要的。因此,通过MTT测定和集落形成实验测试的A549细胞增长,明显被相应剂量的Inulicin处理所抑制。Inulicin抗A549细胞增长活性也表现出剂量依赖性[1]。Inulicin(5, 10, 20 μM)具有几种浓度依赖性效应,包括抑制脂多糖(LPS)诱导的PGE2产生和COX-2表达,阻断NF-κB的激活和转移。此外,Inulicin直接抑制活性NF-κB与特定DNA顺式元件的结合[2]。 |
体内活性 | 给裸鼠单次注射Inulicin(12 mg/kg/日)显著抑制了A549异种移植瘤的生长。在体内,Inulicin处理的异种移植瘤中的微血管形成和Src激活也显著受到抑制。单剂量的Inulicin(12 mg/kg/日,i.p.)显著地抑制了裸鼠中A549异种移植瘤的生长,且Inulicin处理的瘤体重显著轻于对照组载体处理的瘤体重[1]。 |
细胞实验 | HUVECs or A549 cells are plated in 60 mm plates (300 cells/plate). After overnight incubation, cells are treated with applied agents (Inulicin; 5 μM and 10 μM) for 24 h. Cells are then washed, and fresh media are added. After 10 days of incubation, surviving colonies are fixed, stained, and manually counted [1]. |
动物实验 | Male nude mice (4-6weeks old, BALB/c) are used. A549 cells (five million cells in 0.1 mL of culture medium) are subcutaneously injected at the right thigh of nude mice, and treatment is started when the tumors reach an average volume of about 100 mm3. Animals are randomized into two groups with 10 mice per group: (a) Vehicle; (b) 12 mg/kg of Inulicin. Inulicin is injected intraperitoneally (i.p.) daily. The mice are examined daily for toxicity/mortality relevant to treatment, and the tumor is measured with a caliper every two days. The tumor volume (in mm3) is calculated, and the tumor growth curve is presented. At the end of experiments, xenograft tumors are isolated through surgery and weighted [1]. |
别名 | 1-O-Acetylbritannilactone, 旋覆花内酯 |
分子量 | 308.37 |
分子式 | C17H24O5 |
CAS No. | 33627-41-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 45 mg/mL (145.93 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol | 1 mM | 3.2429 mL | 16.2143 mL | 32.4286 mL | 81.0714 mL |
5 mM | 0.6486 mL | 3.2429 mL | 6.4857 mL | 16.2143 mL | |
10 mM | 0.3243 mL | 1.6214 mL | 3.2429 mL | 8.1071 mL | |
20 mM | 0.1621 mL | 0.8107 mL | 1.6214 mL | 4.0536 mL | |
50 mM | 0.0649 mL | 0.3243 mL | 0.6486 mL | 1.6214 mL | |
100 mM | 0.0324 mL | 0.1621 mL | 0.3243 mL | 0.8107 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Inulicin 33627-41-7 Angiogenesis Cytoskeletal Signaling Immunology/Inflammation Neuroscience NF-Κb Tyrosine Kinase/Adaptors FAK NF-κB COX Src Inhibitor inhibit Nuclear factor-κB Nuclear factor-kappaB 1-O-Acetylbritannilactone Cyclooxygenase 旋覆花内酯 inhibitor